Rapid and Durable Responses With the Syk/Jak Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination With Rituximab
Hematological Oncology - United Kingdom
doi 10.1002/hon.30_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley